{"paper_id":"3232606a-ec42-4dd5-9b1e-cb9560d1a9d8","body_text":"Abstract\nObjective\nTo examine the effect of somatostatin analogs on surgically induced endometriosis in rat models.\nStudy design\nEndometrial tissue was implanted onto the abdominal peritoneum of 26 rats that were randomized into 3 groups. The rats in group 1(n = 9) were subcutaneously administered with 0.02 mg/kg/d of octreotide (a short-acting analog)for 28 days . The rats in group 2 (n = 8) were subcutaneously injected with 20 mg/kg of a single dose of a long-acting analogue lanreotide The rats in group 3 were given no medication and served as controls (n = 9).\nResults\nMean volume and histologic score of implants in groups 1 (P < .01 and P < .05, respectively) and 2 (P < .01and P < .05, respectively) were significantly lower than that in group 3. There were significant reductions in vascular endothelial growth factor (VEGF) and matrix metalloproteinase 9 (MMP-9) immunoreactivities in group 1 (0.67 ± 0.50 and 1.22 ± 0.44, respectively; both P < .01) and group 2 (0.71 ± 0.48 and 0.86 ± 0.69, respectively; both P < .01) when compared with the control group (1.78 ± 0.83 and 2.11 ± 0.78, respectively).\nConclusion\nSomatostatin analogs has regressed significantly the size of the endometriotic implants and caused atrophy of these lesions in rats by decreasing explant levels of VEGF and MMP-9.\nSimilar content being viewed by others\nReferences\nFrackiewicz E. Endometriosis: an overview of the disease and its treatment. J Am Pharm Assoc(Wash) 2000;40(5): 645–657.\nBajaj P, Madsen H, Arendt-Nielsen L. Endometriosis is associated with central sensitization: a psychophysical controlled study. J Pain. 2003;4(7):372–380.\nHoward FM. Chronic pelvic pain. Obstet Gynecol. 2003;101(3): 594–611.\nSampson JA. Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obste Gynecol. 1927;14:422–469.\nGleicher N, El-Roeiy A, Confino E, Friberg J. Is endometriosis an autoimmune disease? Obstet Gynecol. 1987;70(1):115–122.\nOsteen KG, Yeaman GR, Bruner-Tran KL. Matrix metalloproteinase and endometriosis. Semin Reprod Med. 2003;21(2):155–164.\nRamon L, Gilabert-Estelles J, Castello R, et al. mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay. Hum Reprod. 2005;20(1):272–278.\nWu MH, Shoji Y, Wu MC, et al. Suppression of matrix metalloproteinase-9 by prostaglandin E2 in peritoneal macrophage is associated with severity of endometriosis. Am J Pathol. 2005;167(4):1061–1069.\nGilabert-Estelle’s J, Ramo’n LA, Espana F, et al. Expression of angiogenic factors in endometriosis: relationship to fibrinolytic and metalloproteinase systems. Hum Reprod. 2007;22(8):2120–2127.\nEel-D Othman, Hornung D, Salem HT, Khalifa EA, El-Metwally TH, Al-Hendy A. Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. Eur J Obstet Gynecol Reprod Biol 2008;137 2: 240–246.\nBourlev V, Volkov N, Pavlovitch S, Lets N, Larsson A, Olovsson M. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction. 2006;132(3):501–509.\nMachado DE, Abrao MS, Berardo PT, Takiya CM, Nasciutti LE. Vascular density and distribution of vascular endothelial growth factor(VEGF) and its receptor VEGFR-2(Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril. 2008;90(1):148–155.\nSharma K, Srikant CB. G protein coupled receptor signaled apoptosis is associated with activation of a cation insensitive acidic endonuclease and intracellular acidifi cation. Biochem Biophys Res Commun. 1998;242(1):134–140.\nLattuada D, Casnici C, Venuto A, Marelli O. The apoptotic effect of somatostatin analogue SMS 201–995 on human lymphocytes. J Neuroimmunol. 2002;133(1–2):211–216.\nMentlein R, Eichler O, Forstreuter F, Held-Feindt, J. Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer. 2001;92(4):545–550.\nWang C, Tang C. Inhibition of human gastric cancer metastasis by ocreotide in vitro and in vivo. Zhonghua Yi Xue Za Zhi. 2002;82(1):19–22.\nVernon MW, Wilson EA. Studies on the surgical induction of endometriosis in the rat. Fertil Steril. 1985;44(5):684–694.\nUygur D, Aytan H, Zergeroğlu S, Batioğlu S. Leflunomide-an immunomodulator induces regression of endometrial explant in a rat model of endometriosis. J Soc Gynecol Investig. 2006;13(5):378–383.\nLebovic DI, Kir M, Casey CL. Peroxisome proliferator–activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril. 2004;82(suppl 3):1008–1013.\nYilmaz B, Sucak A, Kilic S, et al. Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9. Am J Obstet Gynecol. 2010;202(4):368.e1–e8.\nKeenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR, Bukovsky A. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril. 1999;72(1):135–141.\nVercellini P, Crosignani PG, Somigliana E, Berlanda N, Barbara G, Fedele L. Medical treatment for rectovaginal endometriosis: what is the evidence? Hum Reprod. 2009;24:2504–2514.\nFerrero S, Remorgida V, Venturini PL. Current pharmacotherapy for endometriosis. Expert Opin Pharmacother. 2010;11(7):1123–1134.\nHughes E, Brown J, Collins JJ, Farquhar C, Fedorkow DM, Vandekerckhove P. Ovulation suppression for endometriosis. Cochrane Database Syst Rev. 2007;18(3):CD000155.\nSalamonsen LA, Wooley DE. Matrix metalloproteinases in normal menstruation. Hum Reprod. 1996;11(suppl 2):124–133.\nCollette T, Bellehumeur C, Kats R, et al. Evidence for an increased release of proteolytic activity by the eutopic endometrial tissue in women with endometriosis and for involvement of matrix metalloproteinase-9. Hum Reprod. 2004;19(6):1257–1264.\nChung HW, Wen Y, Chun SH, Nezhat C, Woo BH, Lake Polan M. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium in women with endometriosis: a rationale for endometriotic invasiveness. Fertil Steril. 2001;75(1):152–159.\nCollette T, Maheux R, Mailloux J, Akoum A. Increased expression of matrix metalloproteinase-9 in the eutopic endometrial tissue of women with endometriosis. Hum Reprod. 2006;21(12):3059–3067.\nPan H, Sheng JZ, Tang L, Zhu R, Zhou TH, Huang HF. Increased expression of c-fos protein associated with increased matrix metalloproteinase-9 protein expression in the endometrium of endometriotic patients. Fertil Steril. 2008;90(4):1000–1007.\nFasciani A, Quilici P, Biscaldi E, et al. Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions. J Clin Endocrinol Metab. 2010;95(12):5315–5319.\nKaylon L. Bruner-Tran, Kevin G. Antoni J. Duleba. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab. 2009;94(7):2489–2494.\nCakmak H, Basar M, Seval-Celik Y, et al. Statins inhibit monocyte chemotactic protein 1 expression in endometriosis. Reprod Sci. 2012;19(6):572–579.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nSevket, O., Sevket, A., Taner, T. et al. Somatostatin Analogs Regress Endometriotic Implants in Rats by Decreasing Implant Levels of Vascular Endothelial Growth Factor and Matrix Metaloproteinase 9. Reprod. Sci. 20, 639–645 (2013). https://doi.org/10.1177/1933719112461188\nPublished:\nIssue date:\nDOI: https://doi.org/10.1177/1933719112461188","source_license":"public-domain-us","license_restricted":false}